170 related articles for article (PubMed ID: 37096491)
1. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.
Le GH; Gillissie ES; Rhee TG; Cao B; Alnefeesi Y; Guo Z; Di Vincenzo JD; Jawad MY; March AM; Ramachandra R; Lui LMW; McIntyre RS
Expert Opin Investig Drugs; 2023 May; 32(5):401-415. PubMed ID: 37096491
[TBL] [Abstract][Full Text] [Related]
2. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
Højlund M; Correll CU
Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
[TBL] [Abstract][Full Text] [Related]
3. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
[TBL] [Abstract][Full Text] [Related]
4. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
[TBL] [Abstract][Full Text] [Related]
5. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
Kuvarzin SR; Sukhanov I; Onokhin K; Zakharov K; Gainetdinov RR
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509616
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
[TBL] [Abstract][Full Text] [Related]
7. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
Kane JM
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
[TBL] [Abstract][Full Text] [Related]
8. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
[TBL] [Abstract][Full Text] [Related]
10. Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.
Kantrowitz JT
CNS Drugs; 2021 Nov; 35(11):1153-1161. PubMed ID: 34655036
[TBL] [Abstract][Full Text] [Related]
11. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.
Hopkins SC; Ogirala A; Worden M; Koblan KS
Clin Drug Investig; 2021 Dec; 41(12):1067-1073. PubMed ID: 34751928
[TBL] [Abstract][Full Text] [Related]
12. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT
Xiao G; Chen YL; Dedic N; Xie L; Koblan KS; Galluppi GR
Pharm Res; 2022 May; 39(5):837-850. PubMed ID: 35484370
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
Heffernan MLR; Herman LW; Brown S; Jones PG; Shao L; Hewitt MC; Campbell JE; Dedic N; Hopkins SC; Koblan KS; Xie L
ACS Med Chem Lett; 2022 Jan; 13(1):92-98. PubMed ID: 35047111
[TBL] [Abstract][Full Text] [Related]
15. Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.
Feemster JC; Westerland SM; Gossard TR; Steele TA; Timm PC; Jagielski JT; Strainis E; McCarter SJ; Hopkins SC; Koblan KS; St Louis EK
Sleep Med; 2023 Jan; 101():578-586. PubMed ID: 36584503
[TBL] [Abstract][Full Text] [Related]
16. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
Yang SM; Ghoshal A; Hubbard JM; Gackière F; Teyssié R; Neale SA; Hopkins SC; Koblan KS; Bristow LJ; Dedic N
Neuropsychopharmacology; 2024 Jun; 49(7):1091-1103. PubMed ID: 38110609
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.
Correll CU; Koblan KS; Hopkins SC; Li Y; Heather Dworak ; Goldman R; Loebel A
NPJ Schizophr; 2021 Dec; 7(1):63. PubMed ID: 34887427
[TBL] [Abstract][Full Text] [Related]
18. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Dedic N; Wang L; Hajos-Korcsok E; Hecksher-Sørensen J; Roostalu U; Vickers SP; Wu S; Anacker C; Synan C; Jones PG; Milanovic S; Hopkins SC; Bristow LJ; Koblan KS
Mol Metab; 2024 Feb; 80():101883. PubMed ID: 38237896
[TBL] [Abstract][Full Text] [Related]
19. Modafinil for people with schizophrenia or related disorders.
Ortiz-Orendain J; Covarrubias-Castillo SA; Vazquez-Alvarez AO; Castiello-de Obeso S; Arias Quiñones GE; Seegers M; Colunga-Lozano LE
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008661. PubMed ID: 31828767
[TBL] [Abstract][Full Text] [Related]
20. Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT
Isaacson SH; Goldstein M; Pahwa R; Singer C; Klos K; Pucci M; Zhang Y; Crandall D; Koblan KS; Navia B;
Neurol Clin Pract; 2023 Aug; 13(4):e200175. PubMed ID: 37273942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]